Patricio O'Donnell, Cheng Dong, Venkatesha Murthy, Mahnaz Asgharnejad, Xiaoming Du, Ann Summerfelt, Hong Lu, Lin Xu, Jens R Wendland, Eduardo Dunayevich, Derek L Buhl, Robert Litman, William P Hetrick, L Elliot Hong, Laura B Rosen
Several attempts have been made to enhance N-methyl-D-aspartate (NMDA) receptor function in schizophrenia, but they have yielded mixed results. Luvadaxistat, a D-amino acid oxidase (DAAO) inhibitor that increases the glutamate co-agonist D-serine levels, is being developed for the treatment of cognitive impairment associated with schizophrenia. We conducted a biomarker study in patients, assessing several endpoints related to physiological outcomes of NMDA receptor modulation to determine whether luvadaxistat affects neural circuitry biomarkers relevant to NMDA receptor function and schizophrenia...
March 16, 2023: Neuropsychopharmacology